Compare MIRM & NOVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | NOVT |
|---|---|---|
| Founded | 2018 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 2019 | N/A |
| Metric | MIRM | NOVT |
|---|---|---|
| Price | $64.32 | $118.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 1 |
| Target Price | $87.55 | ★ $133.00 |
| AVG Volume (30 Days) | ★ 616.7K | 496.2K |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.46 |
| Revenue | $471,794,000.00 | ★ $960,311,000.00 |
| Revenue This Year | $53.78 | $5.10 |
| Revenue Next Year | $19.91 | $6.75 |
| P/E Ratio | ★ N/A | $82.39 |
| Revenue Growth | ★ 53.66 | 4.07 |
| 52 Week Low | $36.88 | $98.27 |
| 52 Week High | $78.55 | $173.16 |
| Indicator | MIRM | NOVT |
|---|---|---|
| Relative Strength Index (RSI) | 35.49 | 58.13 |
| Support Level | $63.66 | $114.19 |
| Resistance Level | $66.77 | $121.95 |
| Average True Range (ATR) | 2.99 | 3.36 |
| MACD | -0.69 | 1.16 |
| Stochastic Oscillator | 9.63 | 81.92 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.